XFOR Stock Summary and Trading Ideas (X4 Pharmaceuticals | NASDAQ:XFOR)

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals trades on the NASDAQ stock market under the symbol XFOR.

As of January 27, 2026, XFOR stock price was flat at $3.63 with 102,394 million shares trading.

XFOR has a beta of 0.81, meaning it tends to be less sensitive to market movements. XFOR has a correlation of 0.01 to the broad based SPY ETF.

XFOR has a market cap of $317.40 million. This is considered a Small Cap stock.

Last quarter X4 Pharmaceuticals reported $2 million in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-136,350 and exceeded earnings estimates by $.13.

In the last 3 years, XFOR traded as high as $77.25 and as low as $1.35.

The top ETF exchange traded funds that XFOR belongs to (by Net Assets): VTI, VXF, ITWO, URTY.

XFOR has underperformed the market in the last year with a price return of -74.7% while the SPY ETF gained +15.5%. XFOR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.5% and -6.9%, respectively, while the SPY returned +2.9% and 0.0%, respectively.

XFOR support price is $3.51 and resistance is $3.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XFOR shares will trade within this expected range on the day.